LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

20.13 5.01

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.13

Max

20.13

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -127M
Töötajad	517
EBITDA	-12M -134M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+62.36% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	685M 2.9B
Eelmine avamishind	15.12
Eelmine sulgemishind	20.13

Uudiste sentiment

By Acuity

50%

141 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. veebr 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22. veebr 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22. veebr 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22. veebr 2026, 23:21 UTC

Tulu

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22. veebr 2026, 23:20 UTC

Tulu

Nickel Industries 2025 Operating Profit US$126.4 Million

22. veebr 2026, 23:19 UTC

Tulu

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22. veebr 2026, 23:19 UTC

Tulu

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22. veebr 2026, 23:18 UTC

Tulu

Nickel Industries Won't Pay a Final Dividend

22. veebr 2026, 23:16 UTC

Tulu

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22. veebr 2026, 21:35 UTC

Tulu

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22. veebr 2026, 21:34 UTC

Tulu

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22. veebr 2026, 21:34 UTC

Tulu

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22. veebr 2026, 21:33 UTC

Tulu

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22. veebr 2026, 21:33 UTC

Tulu

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22. veebr 2026, 21:28 UTC

Tulu

Ampol Final Dividend A$0.60/Share

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Revenue A$31.37 Billion, Down 10%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21. veebr 2026, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20. veebr 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. veebr 2026, 22:12 UTC

Tulu

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. veebr 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. veebr 2026, 21:23 UTC

Tulu

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. veebr 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. veebr 2026, 21:01 UTC

Omandamised, ülevõtmised, äriostud

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. veebr 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

62.36% tõus

12 kuu keskmine prognoos

Keskmine 32.78 USD 62.36%

Kõrge 40 USD

Madal 25 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

141 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.